State Activities: Impact on the U.S. Pharmaceutical Industry : Market Research Report

State Activities: Impact on the U.S. Pharmaceutical Industry

Published: Jun. 25, 2007 - 35 Pages

Executive Summary: Strategic Considerations; Stakeholder Implications
State Legislatures Taking Action Against Serious Drug Concerns: 2007 State Legislative Bills
Northern States Push for Drug Reimportation: Political Maneuverings Create “Poison Pills”; Vested Interests: Politicians, Lobbyists, and Patients; Effects of Looming Presidential and Congressional Elections
Battle Lines Drawn Over Access to Prescriber-Identifi able Prescription Data: New Hampshire’s Prescription Information Law; AMA National Prescribing Data Restriction Program
Electronic Health Records—Interoperability, Transparency, and Accountability for All: National Health Information Network; State Alliance for e-Health
State Attorneys General Not Afraid to Litigate: State Antitrust Enforcement; Average Wholesale Price Manipulations and State Litigation
Educating Physicians: Evidence-Based Medicine and Counter-Detailing: Pennsylvania’s PACE Program; The Drug Effectiveness Review Project; The Prescription Project
States Are Funding Research That Benefi ts the Pharma Industry: Economic Development Through State Life Sciences Initiatives; Stem Cell Funding Initiatives
Access to Affordable Medicines: State Children’s Health Insurance Program; State Pharmaceutical Assistance Programs; States Push for Generics; Industry’s Helping Hand
Mandatory Human Papillomavirus Vaccine Legislation: Just Another Cancer Drug or First-Ever Vaccine?; A New Challenge for Pharmaceutical Companies
State-Sponsored Universal Health Care: States Taking the Lead on Universal Health Care; Businesses Attempt Health Care Reform
Capturing the Future
Figures: 1. Factors Contributing to Total Prescription Drug Spending Growth, 1988-2016; 2. United States Expenditures on Prescription Drugs, 2000, 2005, and 2016; 3. Prescription Drug State Legislation, 2007; 4. Drug Reimportation Timeline: Politics, Patients’ Rights, and Pharmaceutical Industry Lobbying; 5. Timeline of Select Stem Cell Research Activities in Different States, 2000-2007; 6. SCHIP Funds: Allocation Versus Spending, 1998-2007; 7. State Pharmaceutical Assistance Programs, 2006; 8. Health Insurance Premiums, Percentage Increase, 1996-2006; 9. Status of State Initiatives for Health Care Reform
Sidebars: New Hampshire House Bill 1346—An Act requiring certain persons to keep the contents of prescriptions confi dential [excerpt]; Human Papillomavirus, Cancer, and Sexually Transmitted Disease
Tables: 1. State e-Health Initiatives—Channels for Creating Health Information Technology Networks, 2007; 2. States Take Legal Action Against Pharmaceutical Companies; 3. Relative Advantages of Life Sciences Clusters in Three States, 2002 Appendix—State Drug Assistance Programs, 2007

Abstract

Introduction

In 2005, 17% of the nation's $2 trillion in health care costs was paid by state and local governments, including more than $21.7 billion for prescription drugs; these costs are expected to double over the next ten years. Determined to protect state budgets without cutting essential health care services, state legislatures are enacting laws intended to lower drug costs by regulating the health care and prescription drug industries.

Get the Answers You Need to Shape Your Strategy

As drug costs continue to rise, state legislatures become increasingly proactive, enacting legislation intended to contain costs and to create new kinds of local health care initiatives-and taking legal action against pharmaceutical companies over issues of drug pricing and safety. Can pharmaceutical companies turn this situation around? How can companies adjust their marketing strategies to the requirements of increasingly vigilant national and state governments? In the current environment of distrust, are there opportunities for companies to build mutually benefi cially relationships with the states? In the proliferation of state initiatives in many areas of health care, are there any that may benefit pharmaceutical companies?

Scope

Issues addressed by state legislatures: . drug pricing, drug reimportation, patient/prescriber privacy, electronic medical records, stem cell funding, life sciences research, HPV vaccination, universal health care.
2007 state legislation: . most active states, bills fi led, most frequently targeted pharmaceutical-related issues.
Programs initiated by states: . evidence-based medicine initiatives, Pennsylvania PACE Program, Oregonbased Drug Effectiveness Review Project, the Prescription Project, child health insurance programs, drug purchase assistance, state-funded life sciences research initiatives.
Prescription data protection: . New Hampshire prescription information law, AMA prescribing data restriction program.
Electronic health records: . State Alliance for e-health, individual state initiatives, National Health Information Network.
State legal actions against pharmaceutical companies: . companies targeted, plaintiff states, nature of complaints, settlements awarded.

Please note, the PDF e-mail from publisher version of this report is for a global site license.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/13/2012 - 32

State Activities: Impact on the U.S. Pharmaceutical Industry

Table of Contents

Abstract